Navigation Links
Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Date:8/30/2012

RICHMOND, Calif., Aug. 30, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 6, 2012, at the Stifel Nicolaus Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
3. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
4. Sangamo BioSciences Reports First Quarter 2012 Financial Results
5. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Neurocrine Biosciences Reports Second Quarter 2012 Results
10. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
11. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... ... 24, 2019 , ... Drug resistance has been declared as one of the ... becoming one of the most serious concerns. Hong Kong cannot be spared from the ... (CA-MRSA), or a seven-fold of the figure in 2007 – the year the disease ...
(Date:9/24/2019)... ... September 24, 2019 , ... In the past three years, the National Science ... South Dakota School of Mines & Technology that expands human understanding of ... to form a slimy and yet strong layer which is commonly known as a ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... improve success in chronic diseases, announces today that the U.S. Patent and Trademark ... combinatorial genetic algorithm to rank drug class recommendations for hypertension treatment. , ...
(Date:9/17/2019)... ... 2019 , ... MyBioGate Global Healthcare Innovation Competition Boston Preliminary ... a forum organized by MyBioGate, Inc. and CUBIO Innovation Center that promotes and ... of evaluation, twelve companies out of over 200 applications were selected to compete ...
Breaking Biology Technology:
(Date:10/3/2019)... , ... October 01, 2019 , ... ... pouring and dispensing of chemicals, reagents, and medias and to be a more ... Bag is the culmination of years of experience and feedback from the original ...
(Date:9/30/2019)... ... September 30, 2019 , ... USDM Life Sciences , ... science organizations to accelerate innovation and maximize productivity, announces that David Blewitt will ... Just 30 days to 21 CFR Part 11 compliance with Box, When: Friday, ...
(Date:9/25/2019)... ... 25, 2019 , ... The esteemed dental implant specialists at ... for a variety of procedures, including single tooth replacement, new “teeth-in-a-day” immediately functioning ... implants offer patients permanent tooth replacement solutions that look and function very ...
Breaking Biology News(10 mins):